ACHN is in Beast mode.... I'm not selling until $4.50 at least. Nice job on ACRX. I sold the pop on the NDA acceptance. Should have rebought the dip knowing the EU partner would be coming soon.
Anyways, got my eye on CBMX here into earnings late february. Sell the rip. CBMX always blasts and prelim numbers look like they will have a blowout Q.
Also holding some short positions on GALE. Way overvalued here in my opinion. Using options to mitigate risk. Too much retail buying and buying. Upgrade after upgrade.
Another interesting stock is CMXI. They haven't made a dime and now they have a new reimbursement for their Autolol Gel. The new reimbursment takes profit margins from negative to +30% on sales. Now a profitable company. Earnings will be the key here but the company is CHEAP CHEAP CHEAP. CMXI only trading at 46M mkt cap...
Let me know your thoughts.
Happy thanksgiving to you too kitty! I will definitely be thankful for our beauty SNTS and TSRX this year.
I was holding options before last earnings call in SNTS and it paid half my yearly salary.
Let me know when you find the next undervalued stock like SNTS !
KABOOM KITTY!!! I sold off half my shares on the pop. Was holding 60 contracts as well and dumped those.
Holding 16K shares and some march calls
Here is what I found.
"While we are disappointed that we were not able to resolve the clinical hold at this time despite having addressed all the issues, we believe the breadth of our portfolio allows us to quickly advance other all oral combination regimens for the treatment of HCV," stated Milind Deshpande, President and Chief Executive Officer of Achillion. "With our Phase 2 NS5A inhibitor, ACH-3102, we are in a position to rapidly initiate combination studies with ACH-2684, our protease inhibitor, with results expected in 2014. Further, we continue to advance our uridine-analog nucleotide, ACH-3422, with which we anticipate initiating clinical trials in the first half of 2014."
ACH-2684 has completed all of the necessary preclinical and clinical trials necessary to support advancement into Phase 2 combination development. Achillion previously reported robust anti-viral activity with ACH-2684 as monotherapy including Phase 1b data in both non-cirrhotic and cirrhotic treatment-naïve HCV genotype (GT) 1 patients. In addition, Achillion will continue to work to resolve the clinical hold related to sovaprevir.
Last sentence says Achillion will continue to work to resolve the clinical hold related to sovaprevir. That doesn't say Q2 2014 to me.
Both. A letter is always sent in the mail but they will usually FAX a copy of the letter or send it in an email.
It says "engage in regulatory discussions regarding path forward"
That doesn't mean anything about the clinical hold. The company has responded to the requirements from the FDA regarding the clinical hold. Now it's just a mater of time before the FDA responds and lifts the hold.
They want to engage in regulatory discussions regarding the path forward most likely to design proper primary and secondary endpoints in the study.
In my experience the FDA has never had to have a discussion with us for a clinical hold. Usually they want to see a few more data points and some paperwork to continue the clinical study. They have responded to that request. Usually, the FDA sends a letter to the company to release the hold.
And that usually happens on Thursdays.
Maybe tomorrow we get good news? LOL
Just posted on VTUS board. Getting some thoughts perculating on this. Something big is coming. Insiders bought way too many shares.
Hep C is going to be a big market in the future and it seems bigger pharma has been serving themselves slices of the Hep C pie lately.
Sorry kitty was busy with work yesterday.
This trade is more of a clinical hold release boomer. Market has already priced in all the bad news. The drug interaction was with HIV patients taking Reyataz. The hold was voluntary from the company which later became an FDA hold after review.
This company is severely undervalued and RA capital purchased over 22M shares. Why? One cam only suspect Peter knows something.
Peter is known for finding value in biotechs really early. Where he goes I go at least with a few shares.
I'm currently holding 26k shares at 2.58 average. I'll add more on any dips and have been trading around this position with the ups and downs. There has been a ton of naked shorting going on because I watch the level 2 like a hawk and can see the 100k blocks get filled with no price movement. This is how funds get large positions without price swings.
Then when the time is right. Those hedge funds will blast the stock higher and squeeze out the shorts.
Take a look at ACHN
They got put on clinical hold for a drug-drug interaction and the price sank to $2 range. RA capital has been making some hefty investments in this. With the institutional holdings being so high and 30% short interest if the clinical hold comes off this stock may blow higher a couple of dollars.
FDA has 30 days to respond after the company addresses the FDAs concerns and the hold will be lifted. That news could send shorts in panic mode.
Plus Hep C is a huge market in the coming years. Look at what GILD just paid for a slice of the Hep C pie!
Kitty. Good Luck tomorrow. I was worried of a CRL so I ditched my position. It was a run-up trade anyways.
If news is good, I'll buy it back as I think it will be a surprise to most shorts out there and there will be a good little squeeze. I don't believe we'll see a sell the news in PSDV. But you never know.
NSPR (120M mkt cap with interesting Mguard stent. Potential 3x+ bagger. Data Oct 30)
CYTR (just finished offering - Data December for Phase 2)
RNN (I know you hate cancer bios data readout Q1 2014 - just closed offering 0.52)
RMTI (Still great stock and undervalued)
Just a few. There are so many. I just feel like those have the most potential.